An observational study in Lung Cancer (Diagnosis), sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Shanghai Zhongshan Hospital · Observational
Among 11 studies in Lung Neoplasms by Shanghai Zhongshan Hospital — 6 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Shanghai Zhongshan Hospital.
Among the 11 studies in Lung Neoplasms by Shanghai Zhongshan Hospital, this one is one of 3 that started in 2026, is one of 7 observational ones, and was the 9th registered.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's planned enrollment of 333 is above the median of 200 across 1,434 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →6 of the 11 studies in Lung Neoplasms by Shanghai Zhongshan Hospital are open now, in 1 country. Each count lists the studies.
Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: all sexes.
The full table on the hub →11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2026.
Median enrollment 190 across the 3 interventional studies, 334 across the 8 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
Shanghai Zhongshan Hospital is the lead sponsor of 652 studies on the registry; 291 are open to participants now.
1 of the studies in Lung Neoplasms by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06941948Shanghai Zhongshan HospitalSleep Disorders and Tumor Immune Microenvironment | 2027-01-01 |
Among the 11 studies in Lung Neoplasms by Shanghai Zhongshan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
To investigate the diagnostic performance of Femtosecond Laser Label-Free Imaging combined with artificial intelligence for predicting high-risk pathological features in lung cancer
Lung cancer patients undergoing pulmonary resection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Femtosecond Laser Label-Free Imaging Combined with Artificial Intelligence. The diagnostic results will be blinded to both the physicians (including all clinicians involved in the patient's diagnostic and treatment process, such as surgeons and pathologists) and the patient, and the diagnostic results will NOT affect the original treatment plan.
The primary endpoint is the accuracy of the FLI combined with the AI model in predicting regional lymph node metastasis status in lung cancer, evaluated using postoperative pathology results as the reference standard.
Time frame: through study completion, an average of 2 year
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.